Why RNA ?
Our OneRNA® Platform can assist you developing next generation cures from early R&D through clinical strategy to executing and enrolling patients. Because we don't use panels, the companion diagnostic becomes an algorithm on our platform
ARE YOU DEVELOPING DRUGS?
The OneRNA Platform makes the companion diagnostic into an algorithm
OneRNA for Next Generation Cures
Our OneRNA Platform for the developing next generation cures
From early R&D through clinical strategy to executing and enrolling patients
Expand label of existing drugs
OneRNA® identifies and quantifies all mRNA in the sample
Historically drugs was developed and approved in one tissue type. In many cases the same genetic alteration can be driving breast cancer in one patient, and lung cancer in another, opening up for many more treatment options.
Design basket and umbrella studies
OneRNA® identifies and quantifies all mRNA in the sample
We have design combinatorial study with multiple immune therapy targets and checkpoint inhibitors. Design was able to “enroll” 30% of the target population based on the frequency of altered expression. This suggests that effective enrollment can be achieved using OneRNA® whereas enrollment based on mutations can be difficult due to a low population penetrance of a given mutation
Attract patients to clinical studies
OneRNA® identifies and quantifies all mRNA in the sample
Most clinical studies have multiple biomarker inclusion criteria and there is only limited sample material available to test on. OneRNA® detects 20,000 mRNA at the same time with only 2 scrolls of tissue from an FFPE block. 80% of clinical studies fail due to lack of enrollment.
Companion diagnostic as an algorithm
OneRNA® identifies and quantifies all mRNA in the sample
To develop and validate a companion diagnostic in parallel with a drug is like "landing and airplane on the top of a mountain". OneRNA® decrease the risk by turning the biomarker fishing expedition into a math equation which enables you to develop a responder algorithm that meets the study endpoint.
Design next generation cures
OneRNA® identifies and quantifies all mRNA in the sample
COVID19 demonstrated that we can ge from mRNA code to approved drug in less than 12 month. This is very exciting as it opens up for fast development of the next generation cures and potentially also development of truly individualized mRNA vaccines
Get In Contact with Us
Our current focus is Cancer, however, the OneRNA® Platform is disease-agnostic diagnostic. We welcome the opportunity to work in other indications
@2020